Could six months of targeted therapy be enough for some breast cancer patients?
NCT ID NCT04928261
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether patients with early-stage HER2-positive breast cancer who have a complete response to initial chemotherapy and HER2-targeted therapy can safely receive only 6 months of further HER2 treatment instead of the standard 12 months. The goal is to reduce heart side effects and treatment burden while maintaining effectiveness. The trial will enroll 52 participants across multiple Canadian centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab (Herceptin)
What this could lead to
If successful, this could show that a shorter course of HER2-targeted therapy is safe and effective for patients who have a complete response to initial treatment, reducing heart risks and treatment burden.
What could go wrong
This is a small, single-arm study with only 52 participants, so results may not apply broadly. Shorter therapy might increase the risk of cancer recurrence, and heart side effects remain a concern.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H8M2, Canada